Lorazepam Has Negative Impact on Survival in Pancreatic Cancer
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Aug. 22, 2023 -- Lorazepam stimulates fibrosis and inflammatory signaling and is associated with reduced survival in patients with pancreatic cancer, according to a study published online Aug. 17 in Clinical Cancer Research.
Abigail C. Cornwell, from the Roswell Park Comprehensive Cancer Center in Buffalo, New York, and colleagues examined the association between benzodiazepines (BZD) and pancreatic cancer patient survival outcomes. The impact of lorazepam was examined in the murine pancreatic adenocarcinoma tumor microenvironment. Furthermore, the impact of BZDs was examined on interleukin (IL)-6 expression or secretion by human-immortalized pancreatic cancer-associated fibroblasts (CAFs).
The researchers found that in pancreatic cancer patients receiving chemotherapy, lorazepam was associated with worse progression-free survival (PFS), while alprazolam was associated with improved PFS. Desmoplasia (fibrosis and extracellular matrix protein deposition), inflammatory signaling, and ischemic necrosis were promoted by lorazepam. Preferential expression of GPR68 was seen on human pancreatic ductal adenocardinoma CAFs, and n-unsubstituted BZDs, including lorazepam, significantly increased IL-6 expression and secretion in a pH and GPR68-dependent manner. In contrast, IL-6 was reduced in human CAFs in a pH and GPR68-independent manner by alprazolam and other GPR68 n-substituted BZDs. Relative to alprazolam and patients not receiving BZDs, lorazepam was associated with worse survival outcomes across many cancer types.
"We think the mechanism comes down to a difference in structure between different benzodiazepines," coauthor Michael Feigin, Ph.D., also of the Roswell Park Comprehensive Cancer Center, said in a statement. "Alprazolam has the opposite effect as lorazepam; it has no impact on GPR68, but it potently decreases IL-6, and we think this decreases the inflammatory potential of these tumors."
One author disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
American Association for Cancer Research, April 5-10
The annual meeting of the American Association for Cancer Research was held this year from April 5 to 10 in San Diego, drawing approximately 19,000 participants from around the...
Subclassification Can Tailor Surveillance for Pancreatic Adenocarcinoma
WEDNESDAY, April 17, 2024 -- Subclassification of individuals at high risk for pancreatic adenocarcinoma (PC) can enable the development of surveillance approaches better tailored...
AACR: Exosome-Based miRNA Assay Can Detect Pancreatic Cancer
MONDAY, April 8, 2024 -- An exosome-based liquid biopsy assay can distinguish patients with pancreatic ductal adenocarcinoma (PDAC) from healthy donors (HDs), according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.